You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

CDK6

Showing 1 - 25 of 538
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Cancer Trial in Boston (Abemaciclib)

Recruiting
  • Cancer
  • Boston, Massachusetts
    Dana Farber Cancer Institute
Jan 9, 2023

CDK4/6 Inhibitors Combined With Endocrine Therapy and Subsequent

Not yet recruiting
  • Breast Cancer
  • +3 more
  • Different treatment regimens following progression on CDK4/6 inhibitors.
  • (no location specified)
Sep 5, 2023

Head Neck Cancer, Advanced Cancer, Metastatic Cancer Trial in Bordeaux, Lyon, Nice (Abemaciclib)

Recruiting
  • Head and Neck Cancer
  • +2 more
  • Bordeaux, France
  • +2 more
Jul 22, 2022

Advanced HR-positive and HER2-negative Breast Cancer; CDK4/6 Inhibitor Treatment Failed Trial in Hangzhou (dalpiciclib;

Recruiting
  • Advanced HR-positive and HER2-negative Breast Cancer; CDK4/6 Inhibitor Treatment Failed
  • dalpiciclib; fluvestrant; compound gossypol acetate tablets
  • Hangzhou, Zhejiang, China
    zhejiangCH
Nov 9, 2023

CDK4/6 Inhibitors in Hormone Receptor-positive Advanced Breast

Not yet recruiting
  • Breast Cancer
  • CDK4/6 inhibitor
  • Shanghai, Shanghai, China
    Renji Hospital, School of Medicine, Shanghai Jiao Tong Universit
Apr 5, 2023

Locally Advanced Breast Cancer, Hormone Receptor Positive,HER2-negative Breast Cancer Trial in Jinan (letrozole)

Recruiting
  • Locally Advanced Breast Cancer
  • Hormone Receptor Positive，HER2-negative Breast Cancer
  • Jinan, Shandong, China
    Breast Cancer Center, Shandong Cancer Hospital and Institute
Apr 11, 2023

Breast Cancer Trial in Baltimore (Endocrine Therapy and a CDK 4/6 inhibitor)

Recruiting
  • Breast Cancer
  • Endocrine Therapy and a CDK 4/6 inhibitor
  • Baltimore, Maryland
    Johns Hopkins University
Jul 18, 2022

Advanced Breast Cancer Trial in Lebanon (Fulvestrant, Neratinib, Alpelisib)

Not yet recruiting
  • Advanced Breast Cancer
  • Lebanon, New Hampshire
    Dartmouth Hitchcock Medical Center
Jun 28, 2023

Advanced HR+ HER2 Negative Breast Carcinoma Trial ((CDK)4/6 inhibitor)

Not yet recruiting
  • Advanced HR+ HER2 Negative Breast Carcinoma
  • (CDK)4/6 inhibitor
  • (no location specified)
Sep 27, 2022

Breast Cancer, ER-positive Breast Cancer, HER2-negative Breast Cancer Trial in Miami (AI+CDK4/6i, SERD+CDK4/6i, mTOR inhibitor +

Not yet recruiting
  • Breast Cancer
  • +3 more
  • Miami, Florida
    University of Miami
Apr 12, 2023

Estrogen-receptor-positive Breast Cancer, HER2/Neu-Negative Breast Cancer, Advanced Breast Cancerv Trial in Chicago

Not yet recruiting
  • Estrogen-receptor-positive Breast Cancer
  • +3 more
  • elacestrant, palbociclib, abemaciclib, ribociclib
  • Chicago, Illinois
    Northwestern University
Sep 25, 2023

Hormone Receptor-positive Advanced Breast Cancer Trial (chidamide combined with fulvestrant)

Not yet recruiting
  • Hormone Receptor-positive Advanced Breast Cancer
  • chidamide combined with fulvestrant
  • (no location specified)
Mar 28, 2023

Breast Cancer Trial (RP-6306, Gemcitabine, Observation)

Not yet recruiting
  • Breast Cancer
  • (no location specified)
Jan 26, 2023

Metastatic Breast Cancer Trial (Elacestrant)

Not yet recruiting
  • Metastatic Breast Cancer
  • (no location specified)
Oct 24, 2022

Breast Cancer Metastatic Cancer Trial in Shanghai (Apatinib, Dalpiciclib, Fulvestrant/AI)

Recruiting
  • Breast Cancer Metastatic Cancer
  • Shanghai, Shanghai, China
    Breast cancer institute of Fudan University Cancer Hospital
Feb 26, 2023

COVID-19 Trial in Brandenburg an der Havel (Palbociclib)

Withdrawn
  • COVID-19
  • Brandenburg an der Havel, Germany
    Universitätsklinikum Brandenburg an der Havel
Nov 3, 2022

Breast Cancer Stage IV Trial in Mansoura (comparing both arms as regard the objective response rate, toxicity profile, quality

Recruiting
  • Breast Cancer Stage IV
  • comparing both arms as regard the objective response rate, toxicity profile, quality of life, progression free survival
  • Mansoura, Dakahlia, Egypt
    Oncology center mansoura university
Jan 1, 2023

Breast Cancer, Advanced Breast Cancer Trial in Shanghai (Everolimus 10 mg, CDK4/6 Inhibitor SHR6390, Aromatase inhibitor and

Not yet recruiting
  • Breast Cancer
  • Advanced Breast Cancer
  • Everolimus 10 mg
  • +2 more
  • Shanghai, Shanghai, China
    Fudan University Shanghai Cancer Center
Jul 14, 2023

Learn About Use and Effects of CDK4/6 Inhibitors in Canadian

Active, not recruiting
  • Breast Cancer
    • Kirkland, Quebec, Canada
      Pfizer Canada
    Mar 5, 2023

    Breast Cancer Metastatic Cancer Trial in Shanghai (Fluzoparib, Dalpiciclib, Fulvestrant/AI)

    Recruiting
    • Breast Cancer Metastatic Cancer
    • Shanghai, Shanghai, China
      Breast cancer institute of Fudan University Cancer Hospital
    Feb 26, 2023

    Head Neck Cancer Trial in Birmingham (Cohort 1 Not Previously Treated, Cohort 2 Treated Previously)

    Terminated
    Has Results
    • Head and Neck Cancer
    • Cohort 1 Not Previously Treated
    • Cohort 2 Treated Previously
    • Birmingham, Alabama
      University of Alabama at Birmingham
    Jun 16, 2021

    Neurofibromatosis 1 Trial run by the National Cancer Institute (NCI) (Abemaciclib)

    Recruiting
    • Neurofibromatosis 1
    • Bethesda, Maryland
      National Institutes of Health Clinical Center
    Jan 20, 2023

    CYP3A4*22 Trial (Palbociclib 125Mg Tab, Ribociclib 200Mg Oral Tablet, Abemaciclib 150 MG Oral Tablet)

    Not yet recruiting
    • CYP3A4*22
    • Palbociclib 125Mg Tab
    • +2 more
    • (no location specified)
    Jan 10, 2023

    Breast Cancer Trial in Tianjin (Dalpiciclib, Pyrotinib, Fulvestrant)

    Not yet recruiting
    • Breast Cancer
    • Tianjin, China
      Tianjin Cancer Hospital
    Mar 28, 2023

    Tumors Trial in Seoul (abemaciclib+paclitaxel)

    Active, not recruiting
    • Tumors
    • Seoul, Korea, Republic of
      Severance Hospital
    May 30, 2022